04/29/2024
11:15 PM | Acrivon Therapeutics (Filer)
| Form EFFECT | |
04/26/2024
7:30 AM | Acrivon Therapeutics (Filer)
| Form DEF 14A | |
04/26/2024
7:30 AM | Acrivon Therapeutics (Filer)
| Form DEF 14A | |
04/26/2024
7:33 AM | Acrivon Therapeutics (Filer)
Acrivon Therapeutics (Filer)
| Form DEFA14A | |
04/26/2024
7:36 AM | Acrivon Therapeutics (Filer)
Acrivon Therapeutics (Filer)
| Form ARS | |
04/17/2024
3:39 PM | Acrivon Therapeutics (Filer)
| Form S-3
Registration statement under Securities Act of 1933 | |
04/15/2024
7:53 AM | Acrivon Therapeutics (Issuer)
EDELMAN JOSEPH (Reporting)
PERCEPTIVE ADVISORS LLC (Reporting)
PERCEPTIVE LIFE SCIENCES MASTER FUND LTD (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
|
04/15/2024
7:21 AM | Acrivon Therapeutics (Subject)
PERCEPTIVE ADVISORS LLC (Filed by)
| Form SC 13G/A | |
04/11/2024
3:16 PM | Acrivon Therapeutics (Subject)
RA CAPITAL MANAGEMENT, L.P. (Filed by)
| Form SC 13D/A | |
04/09/2024
6:05 AM | Acrivon Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
03/29/2024
8:06 AM | Acrivon Therapeutics (Filer)
| Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
03/28/2024
7:00 AM | Acrivon Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
03/28/2024
6:36 AM | Acrivon Therapeutics (Filer)
| Form 10-K
Annual report pursuant to Section 13 or 15(d) | |
03/06/2024
3:32 PM | Acrivon Therapeutics (Issuer)
Palani Santhosh (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
03/04/2024
7:15 AM | Acrivon Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
02/16/2024
4:13 PM | Acrivon Therapeutics (Issuer)
Masson Kristina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/16/2024
4:14 PM | Acrivon Therapeutics (Issuer)
Miller Mary (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/14/2024
3:57 PM | Acrivon Therapeutics (Subject)
CITADEL ADVISORS LLC (Filed by)
| Form SC 13G/A | |
02/14/2024
3:36 PM | Acrivon Therapeutics (Subject)
PERCEPTIVE ADVISORS LLC (Filed by)
| Form SC 13G/A | |
02/14/2024
8:51 AM | Acrivon Therapeutics (Subject)
Marshall Wace North America L.P. (Filed by)
| Form SC 13G/A | |
02/13/2024
2:40 PM | Acrivon Therapeutics (Subject)
Sands Capital Ventures, LLC (Filed by)
| Form SC 13G/A | |
02/09/2024
3:37 PM | Acrivon Therapeutics (Issuer)
Magovcevic-Liebisch Ivana (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
02/09/2024
3:34 PM | Acrivon Therapeutics (Issuer)
Magovcevic-Liebisch Ivana (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
02/08/2024
7:27 AM | Acrivon Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
01/19/2024
3:24 PM | Acrivon Therapeutics (Issuer)
Miller Mary (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/16/2024
3:45 PM | Acrivon Therapeutics (Issuer)
Cuillerot Jean-Marie (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
01/12/2024
3:46 PM | Acrivon Therapeutics (Issuer)
Cuillerot Jean-Marie (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
01/08/2024
6:28 AM | Acrivon Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
12/17/2023
11:15 PM | Acrivon Therapeutics (Filer)
| Form EFFECT | |
12/08/2023
3:21 PM | Acrivon Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
12/01/2023
3:35 PM | Acrivon Therapeutics (Filer)
| Form S-3
Registration statement under Securities Act of 1933 | |
11/16/2023
6:41 PM | Acrivon Therapeutics (Issuer)
Blume-Jensen Peter (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/16/2023
6:41 PM | Acrivon Therapeutics (Issuer)
Devroe Eric (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/16/2023
6:41 PM | Acrivon Therapeutics (Issuer)
Gamelin Erick (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/16/2023
6:42 PM | Acrivon Therapeutics (Issuer)
Holm-Jorgensen Rasmus (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/16/2023
6:42 PM | Acrivon Therapeutics (Issuer)
Masson Kristina (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/16/2023
6:43 PM | Acrivon Therapeutics (Issuer)
Miller Mary (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
11/09/2023
8:12 AM | Acrivon Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
11/09/2023
7:02 AM | Acrivon Therapeutics (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
10/19/2023
6:45 PM | Acrivon Therapeutics (Issuer)
Miller Mary (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/28/2023
6:13 PM | Acrivon Therapeutics (Issuer)
Miller Mary (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
Gold Set to EXPLODE! (Ad) Gold has already reached all-time highs, and experts believe it's not slowing down any time soon.
In fact, some analysts predict a $7,000 price tag by 2025. Click here now to download the free Precious Metals Buying Guide! |
09/28/2023
6:17 PM | Acrivon Therapeutics (Issuer)
Miller Mary (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
09/05/2023
4:23 PM | Acrivon Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
08/23/2023
3:19 PM | Acrivon Therapeutics (Issuer)
Blume-Jensen Peter (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
08/11/2023
7:25 AM | Acrivon Therapeutics (Filer)
| Form S-8
Registration statement under Securities Act of 1933 to be offered to employees pursuant to certain plans | |
08/11/2023
6:11 AM | Acrivon Therapeutics (Filer)
| Form 10-Q
General form for quarterly reports under Section 13 or 15(d) | |
08/11/2023
6:17 AM | Acrivon Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/28/2023
3:58 PM | Acrivon Therapeutics (Issuer)
BAUM CHARLES M (Reporting)
| Form 3
Initial statement of beneficial ownership of securities | |
06/28/2023
4:06 PM | Acrivon Therapeutics (Issuer)
BAUM CHARLES M (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/28/2023
2:47 PM | Acrivon Therapeutics (Issuer)
Chione Ltd (Reporting)
Czernik Marcin (Reporting)
Hadjimichael Andreas (Reporting)
Nikolaou Anastasis (Reporting)
Smolokowski Wiaczeslaw (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/22/2023
4:02 PM | Acrivon Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/20/2023
4:15 PM | Acrivon Therapeutics (Issuer)
Chione Ltd (Reporting)
Czernik Marcin (Reporting)
Hadjimichael Andreas (Reporting)
Nikolaou Anastasis (Reporting)
Smolokowski Wiaczeslaw (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/20/2023
4:21 PM | Acrivon Therapeutics (Issuer)
Holm-Jorgensen Rasmus (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/14/2023
5:33 PM | Acrivon Therapeutics (Issuer)
Chione Ltd (Reporting)
Czernik Marcin (Reporting)
Hadjimichael Andreas (Reporting)
Nikolaou Anastasis (Reporting)
Smolokowski Wiaczeslaw (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
06/12/2023
11:20 AM | Acrivon Therapeutics (Subject)
Chione Ltd (Reporting)
| Form 144
Notice of proposed sale of securities pursuant to Rule 144 | |
06/05/2023
4:01 PM | Acrivon Therapeutics (Filer)
| Form 8-K
Current report pursuant to Section 13 or 15(d) | |
06/01/2023
7:40 PM | Acrivon Therapeutics (Issuer)
Blume-Jensen Peter (Reporting)
| Form 4
Statement of changes in beneficial ownership of securities | |
